Nexalis Therapeutics Limited · ASX:NX1
Nexalis Therapeutics — InhaleRx — Shareholder Meeting (May 2025)
29 slides from Nexalis Therapeutics's shareholder meeting presentation, May 29, 2025
Slide 1: Annual General Meeting
ANNUAL GENERAL MEETING 4.00pm AEST, Thursday 29 May 2025
Slide 2: Welcome and Agenda
WELCOME AND AGENDA Online attendees • If you have an IT-related issue, please click on the “Raise Hand” button • If there is a question relating to the resolution, shareholders can ask questions by clicking on the Q&A button and typing in your question Agenda • Annual Financial Statements • Resoluti
Slide 3: 2024 Financial Statements
2024 Financial Statements To consider and receive the financial statements of the Company for the year ended 31 December 2024, consisting of the Financial Report and the Reports of the Directors and Auditor. As required by Section 317 of the Corporations Act, the financial statements of the Company
Slide 4: Resolution 1
RESOLUTION 1 To consider and, if thought fit, to pass, with or without amendment, the following resolution as a non-binding resolution: “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as cont
Slide 5: Resolution 2
RESOLUTION 2 To consider and, if thought fit, to pass with or without amendment, the following resolution as an ordinary resolution: “That Dr Ron Wise, a Director appointed as an additional Director and holding office until the next general meeting of the Company after his appointment in accordance
Slide 6: Resolution 3
RESOLUTION 3 To consider and, if thought fit, to pass with or without amendment, the following resolution as an ordinary resolution: “That Anthony Fitzgerald, a Director appointed as an additional Director and holding office until the next general meeting of the Company after his appointment in acco
Slide 7: Resolution 4
RESOLUTION 4 To consider and, if thought fit, to pass with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of clause 104.2(d) of the Constitution and ASX Listing Rule 14.2 and for all other purposes, Mr Sean Williams, a Director who retires by rotati
Slide 8: Resolution 5
RESOLUTION 5 To consider and, if thought fit, to pass with or without amendment, the following resolution as a special resolution: “That for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue up to that number of Equity Securities equal to 10
Slide 9: Resolution 6
RESOLUTION 6 To consider and, if thought fit, to pass with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 7.2 Exception 13(b), and for all other purposes, approval is given for the issue of equity securities under the “Inhale RX Ince
Slide 10: Resolution 7
RESOLUTION 7 To consider and, if thought fit, to pass with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to the equivalent of $85,656.38 of performance
Slide 11: Resolution 8
RESOLUTION 8 To consider and, if thought fit, to pass with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to the equivalent of $54,886.88 of performance
Slide 12: Resolution 9
RESOLUTION 9 To consider and, if thought fit, to pass with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to the equivalent of $45,210.27 of performance
Slide 13: Resolution 10
RESOLUTION 10 To consider and, if thought fit, to pass with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue an allotment of 2,000,000 unlisted Options, exerc
Slide 14: Resolution 11
RESOLUTION 11 To consider and, if thought fit, to pass with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue an allotment of 500,000 unlisted Options, exercis
Slide 15: Resolution 12
RESOLUTION 12 To consider and, if thought fit, to pass with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue an allotment of 500,000 unlisted Options, exercis
Slide 16: Poll Meeting Formally Closed
POLL Poll opened by the Chair • Click on “For”, “Against” or “Abstain” on Resolutions 1 - 12 • Shareholders and visitors who are not voting, click “Skip Poll” Poll closed by the Chair Results will be released on ASX shortly after conclusion of the Meeting MEETING FORMALLY CLOSED Annual General Meeti
Slide 17: Developing Tomorrow's Inhaled Therapies
Annual General Meeting 29th May 2025 DEVELOPING TOMORROW’S INHALED THERAPIES
Slide 18: Disclaimer
InhaleRx Ltd 29th May 2025 DISCLAIMER This presentation contains summary information about InhaleRx Limited (“InhaleRx” or “IRX” or “Company”) and its activities current as at the date of this presentation. It should be read in conjunction with InhaleRx’ other periodic and continuous disclosure anno
Slide 19: About InhaleRx
19 InhaleRx Ltd 29th May 2025 ABOUT INHALERX InhaleRx Limited (ASX: IRX) is a clinical stage drug development company focused on developing innovative inhaled therapeutics to address unmet medical needs in pain management and mental health treatment. Two drug/device candidates IP Portfolio including
Slide 20: Developing IRX-211 as a Therapeutic Agent
20 InhaleRx Ltd 29th May 2025 DEVELOPING IRX-211 AS A THERAPEUTIC AGENT IRX-211 will be a registered prescription-only medication to treat Breakthrough Cancer Pain (BTcP). Ph1 complete showed excellent tolerability and absorption rates. Cancer Pain Management Market grew from $7.42 billion in 2023 t
Slide 21: Planning to Commence IRX-211
InhaleRx Ltd 29th May 2025 PLANNING TO COMMENCE IRX-211 MILESTONE COMPLETE EXPECTED (QUARTER) Funding Secured Recut of trial design Tender Commenced Spec Work Commenced Component Sourcing HREC Approval for Ph2 trial Protocol Amendment with HREC Batch Manufacturing Scheduled First Patient Screened Q3
Slide 22: Developing IRX-616a as a Therapeutic Agent
22 InhaleRx Ltd 29th May 2025 DEVELOPING IRX-616a AS A THERAPEUTIC AGENT IRX-616a will be a registered prescription-only medication to treat Panic Disorder. Site engaged for Ph1 HREC submission, this trial will be followed by a Ph2 to demonstrate tolerability, safety and efficacy in the Panic Disord
Slide 23: Planning to Commence IRX-616a
InhaleRx Ltd 29th May 2025 PLANNING TO COMMENCE IRX-616a MILESTONE COMPLETE EXPECTED (QUARTER) Funding Secured Medical writing complete Tender Commenced Spec Work Commenced Component Sourcing Tender complete HREC Application Q3* HREC Approval Q3* Batch Manufacturing Scheduled Q3* First Patient Scree
Slide 24: Company Overview
24 InhaleRx Ltd 29th May 2025 COMPANY OVERVIEW Fully Funded to execute clinical development plans $5.7m* across IRX-211 and IRX-616a, to achieve FDA Approvals addressing significant treatment gaps. Market Cap Two shots on Goal – IRX-211 is our flagship medication and further advanced than 616a, howe
Slide 25: Investor Relations Planning
InhaleRx Ltd 29th May 2025 INVESTOR RELATIONS PLANNNG Attracting interest - The overarching plan is to work with partners to attract more eyes to the Company given the plans to commence clinical trials across both programs this year. High Net Worth & Family Office investors– The Company is scoping o
Slide 26: Funding Update
26 InhaleRx Ltd 29th May 2025 FUNDING UPDATE Funding Partner Engaged the company has access of up to unique and exciting $38,5m with Clendon Biotech Capital (CBC) in funding to accelerate our clinical development plans across IRX-211 and IRX-616a. First Draw Down Complete for IRX-211 to lock in the
Slide 27: Summary
InhaleRx Ltd 29th May 2025 SUMMARY Targeting the FDA - Focused on the end goal of New Drug Approvals with the FDA. Funding Partner Activated the company has access of up to unique and exciting $38,5m in funding to accelerate our clinical development plans across IRX-211 and IRX-616a. Significantly r
Slide 28: Thank You
THANK YOU Please contact me at: Darryl Davies darryl.davies@inhalerx.com.au
Slide 29: General Q&A
GENERAL Q&A Annual General Meeting – 29 May 2025